Gy­ro­scope posts ear­ly win with gene ther­a­py for AMD, giv­ing hope for its im­mune com­ple­ment sys­tem tar­get

Gene ther­a­pies for blind­ness are noth­ing new af­ter Roche’s Spark unit hooked an FDA ap­proval for Lux­tur­na back in 2017. But a UK biotech hop­ing to turn its gene ther­a­py against an over­ac­tive im­mune com­ple­ment sys­tem tied to vi­sion loss is now sport­ing da­ta that could help change the game in AMD.

In a Phase I/II dose es­ca­la­tion tri­al, pa­tients who re­spond­ed to Gy­ro­scope’s gene ther­a­py GT005 saw a 146% in­crease in their vit­re­ous Com­ple­ment Fac­tor I lev­els as well as a de­crease in down­stream bio­mark­ers tied to ge­o­graph­ic at­ro­phy for pa­tients with dry AMD, ac­cord­ing to da­ta un­veiled Fri­day at the vir­tu­al An­gio­gen­e­sis, Ex­u­da­tion, and De­gen­er­a­tion meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER